Download MendeleyDiscovery of MK-2118, a Small-Molecule Agonist of STING.
Henderson, T., Altman, M.D., Buevich, A.V., Cash, B., Cemerski, S., Chang, W., Chen, Y., Childers, M., Cumming, J., Dandliker, P.J., Feng, G., Haidle, A., Hayes, R.P., Ho, T., Jewell, J.P., Kariv, I., Knemeyer, I., Kopinja, J., Lacey, B.M., Laskey, J., Lesburg, C.A., Liang, R., Lim, J., Long, B.J., Lu, M., Ma, Y., Minnihan, E.C., Otte, R.D., O'Donnell, G., Pan, B.S., Perera, S.A., Piesvaux, J.A., Presland, J.P., Price, L., Rakhilina, L., Sauvagnat, B., Schroeder, G.K., Sharma, S., Trotter, B.W., Tyagarajan, S., Woo, H., Wyss, D.F., Xu, S., Addona, G.H., Bennett, D.J.(2026) ACS Med Chem Lett 17: 1501-1507
- PubMed: 42445025 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acsmedchemlett.5c00540
- Primary Citation Related Structures:
9PPL - PubMed Abstract:
Agonists of Stimulator of Interferon Genes (STING) have the potential to activate the innate and adaptive immune system for cancer treatment. Early efforts in identifying suitable therapeutics were focused on cyclic dinucleotide (CDN) analogs of 2',3'-cGAMP, the endogenous ligand to STING. CDNs lack of tractable bioavailability led us to consider small-molecule modulators of STING. We previously reported the identification of MSA-2, an orally available non-nucleotide STING agonist with antitumor activity. Optimization efforts in this series faced challenges with uniform activity across species, cell shift, and steep structure activity relationships. Herein we report lead optimization efforts guided by structure-based drug design to identify the MSA-2 analog MK-2118.
- †Department of Discovery Chemistry; ‡Department of Quantitative Biosciences; §Department of Discovery Oncology; ∥Department of Pharmacokinetics; ⊥Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Organizational Affiliation:
